Presley Gerber’s death at a rehabilitation facility has brought back concerns about the risks associated with drug overdose, withdrawal complications, and challenges in addiction recovery. He was the son of Cindy Crawford and Rande Gerber, and he died at 27. The family representative confirmed his death and asked for privacy during their difficult time.
Cause of Death Not Yet Confirmed
The official cause of Presley’s death is still pending although police records suggest a cardiac arrest and potential overdose might have occurred. The Los Angeles County Medical Examiner’s Office conducted an autopsy but has not yet specified the cause of death. Gerber had openly discussed his struggles with substance use and mental health over the years.
Understanding Rehab Risks
Nicholas Kardaris, an expert in addiction treatment, warned against making assumptions about Presley’s death, noting that it could have been due to medical, cardiac, or medication-related issues. He highlighted that treatment facilities can’t entirely eliminate risks related to addiction or withdrawal.
“People are in rehab because they’re struggling with addiction. It doesn’t mean they’re cured of their addiction.”
According to Kardaris, individuals in rehab often have complex medical histories, which can increase risks during recovery.
Withdrawal Risks
Withdrawal poses significant risks itself. Benzodiazepines and alcohol withdrawal can be fatal if not properly monitored. Although opioid withdrawal is uncomfortable, it generally isn’t fatal alone. Kardaris noted that patients might not disclose concurrent withdrawal from other substances like benzodiazepines, which could lead to seizures and other severe complications.
After detox, reduced tolerance to opioids can increase overdose risks. If an individual uses a previously taken dosage post-rehab, the likelihood of a fatal outcome rises.
Ibogaine Treatment Concerns
Gerber’s mention of ibogaine treatment, a non-FDA-approved substance, raises concerns. Kardaris cautioned about the unregulated use of psychoactive treatments like ketamine, ayahuasca, and ibogaine, emphasizing the need for further research and regulation.
Ibogaine is experimentally studied for treating opioid disorder but lacks comprehensive safety and effectiveness data, making its use controversial and uncertain.
Family’s Role in Treatment Program Selection
Kardaris advised families to thoroughly investigate treatment centers to ensure licensed professionals manage patient care. Facilities should have reputable protocols for dealing with withdrawal, medication management, and emergencies. Selecting well-regarded programs with qualified personnel is crucial for effective and safety-focused treatment.